# Repligen Is Betting the Next Big IP War in Biopharma Won’t Be About Molecules

- slug: repligen-is-betting-the-next-big-ip-war-in-biopharma-wont-be-about-molecules
- date: 2026-04-15
- category: Biotech & Life Sciences

Repligen took equity in Novasign in September 2025 before announcing the partnership in July. The order tells you where biopharma manufacturing IP is heading: away from molecules, toward process data.

---